GoAI
Get started
BioStem Technologies, Inc. logo

BioStem Technologies, Inc.

BSEM

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$3.54

−$0.14 · -3.80%

Aug 21, 4:00 PM ET

BSEM company overview

Regular session · ET · Market data may be delayed.

Company profile

Company website

BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Jason Matuszewski
Listed since
Mar 17, 2015
Employees
73

Market position

Day range

Current $3.54

52-week range

Current $3.54

Open
$3.69
Previous close
$3.68
Volume
63.39K
0.93× average
Average volume
68.28K
Average daily volume
Market cap
60.12M USD
Beta
0.26
Market reference 1
50-day average
$3.6013
-1.70% below average
200-day average
$4.4719
-20.84% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
37.52M USD
P/E (TTM)
-2.13×
P/B (TTM)
2.22×
P/S (TTM)
-1×
EV / EBITDA
-79.87×
Earnings yield
-10.33%
Free cash flow yield
10.34%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
112.77%
Operating margin
38.70%
Net margin
46.91%
Return on equity
-16.81%
Return on assets
-13.15%
Return on invested capital
-1.62%

Financial health

Debt / equity
0.04×
Current ratio
4.12×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends115%36%-43%-123%Gross margin, FY2021: 66.03%Gross margin, FY2022: 87.17%Gross margin, FY2023: 92.44%Gross margin, FY2024: 95.37%Gross margin, FY2025: 93.13%Operating margin, FY2021: -36.99%Operating margin, FY2022: -68.09%Operating margin, FY2023: -46.62%Operating margin, FY2024: 10.34%Operating margin, FY2025: -1.45%Net margin, FY2021: -33.30%Net margin, FY2022: -102.90%Net margin, FY2023: -50.84%Net margin, FY2024: 10.56%Net margin, FY2025: -13.86%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 66.03%. Gross margin FY2022 87.17%. Gross margin FY2023 92.44%. Gross margin FY2024 95.37%. Gross margin FY2025 93.13%. Operating margin FY2021 -36.99%. Operating margin FY2022 -68.09%. Operating margin FY2023 -46.62%. Operating margin FY2024 10.34%. Operating margin FY2025 -1.45%. Net margin FY2021 -33.30%. Net margin FY2022 -102.90%. Net margin FY2023 -50.84%. Net margin FY2024 10.56%. Net margin FY2025 -13.86%.

Income trends

Revenue

47.48M USD-84.27%

Operating income

−689.15K USD−31.89M USD

Net income

−6.58M USD−38.47M USD
Income trends across reported periods332.86M USD208.73M USD84.61M USD−39.51M USDRevenue, FY2021: 4.34M USDRevenue, FY2022: 6.88M USDRevenue, FY2023: 16.69M USDRevenue, FY2024: 301.83M USDRevenue, FY2025: 47.48M USDOperating income, FY2021: −1.61M USDOperating income, FY2022: −4.68M USDOperating income, FY2023: −7.78M USDOperating income, FY2024: 31.2M USDOperating income, FY2025: −689.15K USDNet income, FY2021: −1.45M USDNet income, FY2022: −7.07M USDNet income, FY2023: −8.48M USDNet income, FY2024: 31.88M USDNet income, FY2025: −6.58M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 4.34M USD. Revenue FY2022 6.88M USD. Revenue FY2023 16.69M USD. Revenue FY2024 301.83M USD. Revenue FY2025 47.48M USD. Operating income FY2021 −1.61M USD. Operating income FY2022 −4.68M USD. Operating income FY2023 −7.78M USD. Operating income FY2024 31.2M USD. Operating income FY2025 −689.15K USD. Net income FY2021 −1.45M USD. Net income FY2022 −7.07M USD. Net income FY2023 −8.48M USD. Net income FY2024 31.88M USD. Net income FY2025 −6.58M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue47.48M USD301.83M USD16.69M USD6.88M USD4.34M USD
Cost of goods sold3.26M USD13.75M USD1.26M USD881.75K USD1.47M USD
Gross profit44.22M USD287.86M USD15.42M USD5.99M USD2.87M USD
Research and development7.09M USD1.91M USD342K USD123.31K USD119.65K USD
Selling, general, and administrative37.82M USD254.75M USD22.63M USD10.21M USD4.19M USD
Operating expenses44.91M USD256.66M USD23.2M USD10.67M USD4.47M USD
Interest income413.85K USD————
Interest expense—587.22K USD700.33K USD468.15K USD525.88K USD
Depreciation and amortization219.42K USD293.22K USD229.02K USD243.42K USD283.9K USD
Operating income−689.15K USD31.2M USD−7.78M USD−4.68M USD−1.61M USD
Net income−6.58M USD31.88M USD−8.48M USD−7.07M USD−1.45M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
27%
3 beats, 8 misses, 0 met estimates
Average EPS surprise
-327.62%
11 comparable reports
Latest EPS result
-0.52
Estimate -0.5 · Miss by 4.00%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates1.40.66-0.08-0.82Q2 '25BeatQ2 '25MissQ3 '25MissQ4 '25BeatQ1 '26MissQ2 '26MissQ3 '26MissQ4 '26Estimate
Q2 2025, reported Apr 14, 2025: actual 0.94, estimate 0.37, surprise +154.05%, Beat. Q2 2025, reported May 12, 2025: actual 0.17, estimate 1.25, surprise -86.40%, Miss. Q3 2025, reported Aug 14, 2025: actual -0.03, estimate 0.32, surprise -109.38%, Miss. Q4 2025, reported Nov 13, 2025: actual 0.03, estimate 0.02, surprise +50.00%, Beat. Q1 2026, reported Mar 24, 2026: actual -0.67, estimate 0.02, surprise -3450.00%, Miss. Q2 2026, reported May 14, 2026: actual -0.52, estimate -0.28, surprise -85.71%, Miss. Q3 2026, reported Aug 12, 2026: actual -0.52, estimate -0.5, surprise -4.00%, Miss. Q4 2026, reported Nov 12, 2026: actual —, estimate -0.46, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates110.65M75.38M40.11M4.85MQ2 '25BeatQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26MissQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q2 2025, reported Apr 14, 2025: actual 102.87M USD, estimate 86.68M USD, surprise +18.68%, Beat. Q2 2025, reported May 12, 2025: actual 72.5M USD, estimate 101.1M USD, surprise -28.29%, Miss. Q3 2025, reported Aug 14, 2025: actual 49.3M USD, estimate 78.2M USD, surprise -36.96%, Miss. Q4 2025, reported Nov 13, 2025: actual 10.47M USD, estimate 55.2M USD, surprise -81.03%, Miss. Q1 2026, reported Mar 24, 2026: actual 10.1M USD, estimate 55.2M USD, surprise -81.70%, Miss. Q2 2026, reported May 14, 2026: actual 6.14M USD, estimate 5.7M USD, surprise +7.64%, Beat. Q3 2026, reported Aug 12, 2026: actual 7.9M USD, estimate 6.35M USD, surprise +24.36%, Beat. Q4 2026, reported Nov 12, 2026: actual —, estimate 7.96M USD, surprise —, Comparison unavailable.

BSEM peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

Continue in GoAI

Research BSEM

research.disclaimer